<DOC>
	<DOCNO>NCT00780156</DOCNO>
	<brief_summary>Background Drug-eluting stent ( DES ) extremely successful reduce restenosis need repeat revascularization procedures patient undergo PCI . The potential increase incidence late stent thrombosis prompt cardiologist prolong use dual anti-platelet therapy one year duration recommend recent ESC guideline . However , premise cardiologist put patient dual clopidogrel-aspirin regimen life sound easy way , unrealistic goal potential increase bleed complication healthcare cost increase . The recent possibility monitor aspirin bedside assay offer real opportunity compare good aspirin responder patient two strategy : aspirin-clopidogrel regimen versus mono-aspirin regimen respond key question : investigator switch dual single antiplatelet therapy six month good aspirin responder patient ? Study National , multicenter , randomise prospective open group comparison dual clopidogrel-ASA versus single ASA regimen six month , good ASA responder patient treat DES ( name : XIENCE ) implantation . End point Primary : At 12 month : death , myocardial infarction , repeat urgent revascularization , stroke require new hospitalisation major bleeding . Secondary : Incidence 24 36 month drug elute stent ( name : XIENCE ) implantation , composite endpoint incidence 12 , 24 36 month minor bleed complication Participating centre : 60 french center Date study beginning : November 2008 Duration inclusion : 9 month Duration study : 45 month</brief_summary>
	<brief_title>The ITALIC Study : Is There A LIfe Drug-eluting Stents ( DES ) After Discontinuation Clopidogrel</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Male female subject ≥ 18 year age eligible PCI least one drug elute stent ( name : Xience ) implant clinical situation exclude primary PCI acute MI treatment leave main artery . Male female subject ≥ 18 year age eligible PCI least one DES Xience . Patient pretreated protein IIb/IIIa inhibitor ( name : abxicimab eptifibatide ) hospitalization Patient pretreated aspirin clopidogrel PCI ASA check least 24 hour interruption tirofiban The subject give write inform dated consent participate study . Subjects able give inform consent Prior implantation DES Known platelet &lt; 100 000/µl know hemorrhagic diathesis Oral anticoagulation treatment abxicimab eptifibatide hospitalization ASA check le 24 hour interruption tirofiban Thrombolytic therapy within 4 day ASA check Contraindication aspirin clopidogrel Recent major surgery &lt; 6 week Evidence active gastrointestinal urogenital bleeding Severe liver insufficiency Primary PCI acute MI Left main PCI Any schedule surgery year enrollment Severe concomitant disease life expectation &lt; two year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Dual antiplatelet therapy</keyword>
	<keyword>bleeding</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>follow-up drug elute stent</keyword>
</DOC>